HCC
Clinical trials for HCC explained in plain language.
Never miss a new study
Get alerted when new HCC trials appear
Sign up with your email to follow new studies for HCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
AI may help decide who gets immunotherapy after liver cancer surgery
Disease control Not yet recruitingThis study will test whether a deep learning computer model can help doctors decide which liver cancer patients should receive immunotherapy (PD-1 inhibitors) after surgery to prevent the cancer from returning. About 300 patients who have had their liver cancer completely removed…
Matched conditions: HCC
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New four-drug cocktail targets tough liver cancers with promising early trial
Disease control Not yet recruitingThis study tests a new combination of four treatments for people with liver cancer that cannot be removed by surgery and who also have high blood pressure in the liver (portal hypertension). The goal is to see if adding a blood-pressure drug (carvedilol) to standard cancer therap…
Matched conditions: HCC
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New combo aims to stop liver cancer from coming back
Disease control Not yet recruitingThis phase II trial tests whether giving the immunotherapy drug sintilimab along with targeted radiation before surgery can lower the risk of liver cancer returning. About 110 patients with resectable liver cancer will be randomly assigned to receive the combination therapy befor…
Matched conditions: HCC
Phase: PHASE2 • Sponsor: Lei ZHAO • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Liver cancer battle: which combo therapy wins?
Disease control Not yet recruitingThis study compares two treatment combinations for advanced liver cancer that cannot be removed by surgery. One group gets TACE (a procedure that blocks blood flow to the tumor and delivers chemo directly) plus immunotherapy and a targeted drug. The other group gets HAIC (a conti…
Matched conditions: HCC
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Liver cancer trial aims to boost immunotherapy with targeted chemo
Disease control Not yet recruitingThis phase 2 trial tests whether adding a targeted chemo procedure (TACE) to standard immunotherapy can improve outcomes for people with unresectable liver cancer. About 90 participants will receive either atezolizumab/bevacizumab or durvalumab/tremelimumab plus TACE. The goal is…
Matched conditions: HCC
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:38 UTC
-
New scan aims to better detect liver tumors
Diagnosis Not yet recruitingThis early study will test a special imaging agent that targets a protein found on liver cancer cells. Six people with suspected or confirmed liver cancer will receive a low-dose radioactive tracer and then have a SPECT-CT scan. The goal is to see how the tracer moves through the…
Matched conditions: HCC
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Blood test may predict liver cancer comeback and immunotherapy success
Knowledge-focused Not yet recruitingThis study looks at whether a blood test that detects tiny bits of tumor DNA (called minimal residual disease) can predict if liver cancer will come back after surgery. Researchers will test 276 patients before and after surgery to see if the test can also identify who might bene…
Matched conditions: HCC
Phase: NA • Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC